Login to Your Account

Cash-Starved Pharming Spins Out DNage; But is it Enough?

By Cormac Sheridan

Wednesday, May 19, 2010
With its lead product Rhucin (recombinant C1 inhibitor) under regulatory review in Europe and its cash balance dwindling rapidly, Pharming Group NV is battening down the hatches by spinning out DNage BV, a firm it acquired in 2006. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription